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INRODUCTION                                         
The treatment of acute pancreatitis is purely symptomatic   because there is no 
effective therapy to prevent the activation of inflammatory and proteolytic 
cascades. This vicious cycle of cell signalling is believed to be triggered by 
bacterial infection, predominately Gram-negative strains. The most likely 
hypothetical source of the bacterial infection is the gastrointestinal tract. 
Bacterial translocation is caused by increased permeability in the gut and a 
consequent migration of macromolecules such as bacteria,endotoxins and 
antigens from the gastrointestinal tract to the portal system, mesenteric lymph 
nodes, liver, spleen and pancreas. This process leads to the stimulation of 
macrophages, circulatory neutrophils and granulocytes, and then the release of 
pro-inflammatory cytokine causes an inflammatory response. If the 
inflammatory response, which is initially part of the defence mechanisms of the 
host, is over-activated, it may turn into a self-destructive process. The 
unbalanced production of inflammatory mediators might lead to the 
development of systemic inflammatory response syndrome (SIRS), infectious 
pancreatic necrosis and ultimately multi-organ failure (MOF)1 
Severe acute pancreatitis (SAP) represents a typical model of septic syndrome 
due to a failure of the gut barrier .Hence, one of the main therapeutic goals in 
AP is to maintain gut integrity to prevent bacterial and endotoxin translocation 
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AIMS AND OBJECTIVES 
a) To assess the occurrence of infective & non infective complications in 
both types of feeding 
b) To assess the average duration of hospital stay in both groups 
c) To compare the effects of early enteral feeding with parenteral feeding in 
acute pancreatitis 
 
PLACE OF STUDY 
Department of general surgery 
Stanley medical college 
Chennai 
Duration   
 
DURATION 
1 year 
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INCLUSION CRITERIA 
1. Age > 18 years and < 70 years 
2. Mild and moderate in severity 
 
 
 
EXCLUSION CRITERIA 
1. Age < 18 years and >70 years 
2. Severe acute pancreatitis 
3. signs of shock at the time of presentation 
 
ETHICAL COMMITTIE APPROVAL 
 Obtained 
 
POPULATION 
Cases      -  30 
Controls  - 30 
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METHODOLOGY 
1. all the patients who are admitted in the ward with upper abdominal pain 
are evaluated  
2. the diagnosis of pancreatitis will be made clinically,biochemically & 
radiologically 
3. severity will be assessed by BISAP scoring system & CT SEVERITY 
INDEX 
4. early enteral feeding will be started in cases within 24 to 48 hours of 
admission 
5. patients who will be on nil per mouth and on parenteral feeding is 
considered as controls 
6. incidence of complications & course of hospital stay will be observed in 
both cases & controls 
7. datas will be collected & analysed 
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                                    REVIEW OF LITERATURE 
PANCREAS 
The pancreas is an important organ situated in the deep centre of the abdomen.it 
is called as unforgiveful organ because the minor manipulation or minor trauma 
can leads to the morbitidy. 
GROSS ANATOMY 
The pancreas is a composite gland having exocrine acini which discharge their 
secretions into the duodenum to assist in digestion, and groups of endocrine 
cells, the islets of Langerhans, whose role is in carbohydrate metabolism. In 
shape the gland resembles the upper end of a thick walking-stick or hook, lying 
sideways with the handle or hook on the right and turned downwards . Its 
length is about 15 cm. The gland is of firm consistency, and its surface is finely 
lobulated. Its big head on the right is connected by a short neck to the body, 
which crosses the midline and tapers to a narrow tail on the left. The head and 
tail incline towards the paravertebral gutters, while the neck and body are 
curved boldly forward over the inferior vena cava and aorta in front of the first 
lumbar vertebra. The gland lies somewhat obliquely, sloping from the head 
upwards towards the tail behind the peritoneum of the posterior abdominal wall. 
The transpyloric plane (L1) is the guide to the surface marking; the neck 
lies on the plane, which passes across the head and body, and below the tail. 
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 LOCATION OF PANCREAS 
 
 
 Pancreas is an elongated, accessory digestive gland that lies 
retroperitoneally  
  Transversely across the posterior abdominal wall posterior to the 
stomach between duodenum on the right and the spleen on the left 
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PARTS OF PANCREAS 
 
NECK 
T he neck is best defined as the narrow band of pancreatic tissue that lies in 
front of thecommencement of the portal vein, continuous to the right with the 
head and to the left with the body 
HEAD 
The head, the broadest part of the pancreas, is moulded to the C-shaped 
concavity of the duodenum, which it completely fills. It lies over the inferior 
vena cava and the right and left renal veins, mainly at the level of L2 vertebra 
 
 
 8 
 
BODY 
The body of the pancreas passes from the neck to the left, sloping upwards 
across the left renal veinand aorta, left crus of the diaphragm, left psoas muscle 
and lower part of left suprarenal gland, to the hilum of the left kidney. 
 
THE PANCREATIC DUCTS 
 
The pancreatic duct (of Wirsung) is a continuous tube running from the tail to 
the head, gradually increasing in diameter as it receives tributaries. At the 
hepatopancreatic ampulla . it is joined at an angle of about 60° by the bile duct 
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and the manner of their joint opening into the duodenum . In intubation of the 
ampulla for endoscopic retrograde cholangiopancreatography (ERCP), the 
catheter preferentially enters the pancreatic duct. 2 
NEUROANATOMY 
Parasympathetic vagal fibres, which are capable of stimulating exocrine 
secretion, reach the glandmainly from the posterior vagal trunk and coeliac 
plexus, but, as with the gallbladder, hormonal control is more important than the 
neural. Sympathetic vasoconstrictor impulses are derived from spinal cord 
segments T6–10 via splanchnic nerves and the coeliac plexus, the 
postganglionic fibres running to the gland with its blood vessels. As with other 
viscera, pain fibres accompany the sympathetic supply, so that pancreatic pain 
may radiate in the distribution of thoracic dermatomes 6–10 
HISTOLOGY & PHSIOLOGY 
In response to a meal, the pancreas secretes digestive enzymes in an alkaline 
(pH 8.4) bicarbonate-rich fluid. Spontaneous secretion is minimal; the hormone 
secretin, which is released from the duodenal mucosa, evokes a bicarbonate-rich 
fluid. Cholecystokinin (CCK) (synonym: pancreozymin) is released from the 
duodenal mucosa in response to food. CCK is responsible for enzyme release. 
Vagal stimulation increases the volume of secretion. Protein is synthesised at a 
greater rate (per gram of tissue) in the pancreas than in any other tissue, with the 
possible exception of the lactating mammary gland. About 90 per cent of this 
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protein is exported from the acinar cells as a variety of digestive enzymes. 
Approximately 6–20 g of digestive enzymes enter the duodenum each day. 
Nascent proteins are synthesised as preproteins and undergo modification in a 
sequence of steps. The proteins move from the rough endothelial endoplasmic 
reticulum to the Golgi complex, where lysosomes and mature zymogen storage 
granules containing proteases are stored, and then to the ductal surface of the 
cell, from which they are extruded by exocytosis. During this phase, the 
proteolytic enzymes are in an inactive form, the maintenance of which is 
important in preventing pancreatitis.3 
EXOCRINE PANCREAS 
The pancreas secreting 500 to 800 mL per day of colorless, odorless, alkaline, 
isosmotic pancreatic juice. Pancreatic juice is the combination of acinar cell and 
duct cell secretions. The acinar cells secrete amylase,proteases, and lipases, 
enzymes and which are  responsible for the digestion of all three food types 
carbohydrate, protein, and fat. The acinar cells are pyramid shaped, and their 
apices facing the lumen of  acinus. Near the apex of the each cell are numerous 
enzyme-containing zymogen granules that fuse with  apical cell membrane . 
Unlike the endocrine pancreas, inhich islet cells specialize in the secretion of 
one hormone type, individual acinar cells are secreting all types of enzymes. 
However, the ratio of  different enzymes  which is adjusted to the composition 
of digested food through nonparallel regulation of the secretion 
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STRUCTURE OF THE ACINAR CELL 
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The amylase from pancreas is secreted in its active form and completes the 
digestive process already begun by  thesalivary amylase. Amylase is  only 
pancreatic enzyme secreted in its active form, and it hydrolyzes starch and  the 
glycogen to glucose, maltose, maltotriose, and dextrins. These simple sugars are 
transported across  brush border of the intestinal epithelial cells by active 
transport mechanisms. Gastric hydrolysis of protein yields peptides that enter t 
intestine and stimulate intestinal endocrine cells to release cholecystokinin 
(CCK)-releasing peptide, CCK, and secretin, and that stimulate the pancreas to 
secrete enzymes and bicarbonate into the intestine. 
The proteolytic enzymes are secreted as proenzymes that require activation. 
Trypsinogen is converted to its active form, trypsin, by enterokinase, which is 
produced by the duodenal mucosal cells. Trypsin,  activates the other 
proteolytic enzymes. Trypsinogen activation within the pancreas is prevented by 
the presence of trypsinogen activation inhibitors that are also secreted by the 
acinar cells. A failure to express a normal trypsinogen activation  inhibitor, 
pancreatic secretory trypsin inhibitor (PSTI) is also known as serine protease 
inhibitor Kazal type 1 , is a cause of familial pancreatitis. Inhibition of 
trypsinogen activation ensures that the enzymes within the pancreas remain in 
the inactive precursor state and are activated only after entering into the 
duodenum. Hereditary pancreatitis occurs because  of the the missense mutation 
of cationic trpsinogen.4 
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 Chymotrypsinogen is activated to form  thechymotrypsin .Elastase, 
carboxypeptidase A and B, and phospholipase are also activated by  the trypsin. 
Trypsin, chymotrypsin, and elastase are cleaving bonds between amino acids 
within the target peptide chain, and carboxypeptidase A and B cleave amino 
acids at the end of  the peptide chains. Individual amino acids and small 
dipeptides are then actively transported into the intestinal epithelial cells. 
Pancreatic lipase hydrolyzes the triglycerides to 2-monoglyceride and fatty acid. 
Pancreatic lipase is secreted in an active form. Colipase is also secreted by  
pancreas and binds to lipase, changing its molecular configuration and 
increasing its activity. 
Pancreas secretes phospholipase A2 a proenzyme that becomes activated by 
trypsin. Phospholipase A2 hydrolyzes the phospholipids and, as with all lipases, 
requires bile salts for its action. Carboxylic ester hydrolase and  the cholesterol 
esterase hydrolyze  the neutral lipid substrates like esters of cholesterol, 
fat-soluble vitamins, a triglycerides. The hydrolyzed fat is then packaged into 
micelles for transport into intestinal epithelial cells, where the fatty acids are 
reassembled and packaged inside chylomicrons for the  transport through the 
lymphatic system into the bloodstream. The centroacinar and intercalated duct 
cells are secreting the water and electrolytes present in the pancreatic juice.  
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About  40 acinar cells were arranged into a spherical unit called an acinus. 
Centroacinar cells were located near the center of the acinus and were 
responsible for fluid and electrolyte secretion. These cells contain the enzyme 
carbonic anhydrase, which is needed for  the bicarbonate secretion. The amount 
of bicarbonate secreted varies with the pancreatic secretory rate, with greater 
concentrations of  the bicarbonate was secreted as the pancreatic secretory rate 
increases. Chloride secretion varies inversely with the bicarbonate secretion 
such that the sum of these two remains constant. In contrast, sodium and 
potassium concentrations are kept constant throughout the spectrum of  the 
secretory rates . The duodenal mucosal cells are releasing secretin in response to 
acidic chyme passing through the pylorus into the duodenum. Secretin is the 
major stimulant for the  bicarbonate secretion, which buffers the acidic fluid 
entering the duodenum from the stomach. CCK  stimulated bicarbonate 
secretion, but to a much lesser extent than secretin. CCK  is potentiating 
secretin-stimulated bicarbonate secretion. Gastrin and acetylcholine, both are 
the stimulants of gastric acid secretion, are also weak stimulants of the  
pancreatic bicarbonate secretion. Truncal vagotomy is producing  a myriad of 
complex effects on the downstream digestive tract, but the sum effect on the 
exocrine pancreas is the  reduction in bicarbonate and fluid secretion. The 
endocrine pancreas is influencing the adjacent exocrine pancreatic secretions. 
Somatostatin, pancreatic polypeptide (PP), and glucagon are all thought to 
inhibit exocrine secretion. The acinar cells release pancreatic enzymes from 
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theirzymogen granules into the lumen of the acinus, and these proteins combine 
with the water and bicarbonate secretions of the centroacinar cells. The 
pancreatic juice then travels into  the small intercalated ducts. Several small 
intercalated ducts join to form the  interlobular duct. Cells in the interlobular 
ducts contribute fluid and electrolytes to adjust the final concentrations of the 
pancreatic fluid. Interlobular ducts are joining to form about 20 secondary ducts 
that empty into the main pancreatic duct. Destruction of the branching ductal 
tree from recurrent inflammation, scarring, and deposition of stones eventually 
contributing  to the destruction of the exocrine pancreas and the exocrine 
pancreatic insufficiency.5 
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ACUTE PANCREATITIS 
 The definition of acute pancreatitis is “acute condition presenting with 
abdominal pain and is usually associated with the  raised pancreatic enzyme 
levels in the blood or urine as a result of pancreatic inflammation”. Acute 
pancreatitis may recur. 
The mechanism of acute pancreatitis  is thought to be premature activation of 
pancreatic enzymes within the pancreas, leading to a process of autodigestion. 
Anything that injures the acinar cell and impairs the secretion of zymogen 
granules, or damages the duct epithelium and thus delays enzymatic 
secretion, can trigger acute pancreatitis. Once cellular injury has been initiated, 
the inflammatory process can lead to pancreatic oedema, haemorrhage and, 
eventually, necrosis6 
 
Etiologies of acute pancreatitis 
A. Alcohol 
B. Biliary tract disease 
C. Hyperlipidemia 
D. Hereditary 
E. Hypercalcemia 
F. Trauma External 
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Surgical 
     Endoscopic retrograde cholangiopancreatography 
      Hypoperfusion 
      Atheroembolic 
G. Vasculitis 
H. Pancreatic duct obstruction 
I. Neoplasms 
J. Pancreas divisum 
K. Ampullary and duodenal lesions 
L. Infections 
M. Venom 
N. Drugs 
O. Idiopathic 
GALL STONES 
There are several school of thoughts 
1.The mechanism by which the  small gallstones  are passing  down the 
common bile duct and  past the pancreatic duct junction and into the duodenum, 
causing acute pancreatitis 
2. Another school of thought is that transient incompetence occurs by the 
passage of a stone through the sphincter may allow  the back flow of duodenal 
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fluid and bile into the pancreatic duct, but this is refuting by the usual absence 
of acute pancreatitis after endoscopic sphincterotomy or surgicalsphinteroplasty.  
3.A third school of thought  is that acute pancreatitis is due to a gallstone 
obstructing the pancreatic duct that  leading to ductal hypertension. It is being 
postulated that this backpressure might lead to  the minor ductal disruption, 
extravasation of pancreatic juice into the less alkaline interstitium of the  the 
pancreas, and promotion of enzyme activation.  
ALCOHOL 
 There are several mechanisms by which ethanol causes acute pancreatitis. 
1.Ethanol is a  toxin to pancreatic acinar cells and it  causes a brief secretory 
increase followed by inhibition. The secretory increase coupled with  spasm of 
the sphincter of Oddi is causing incite acute pancreatitis.  
2.Ethanol is inducing ductal permeability, that allow premature activation of 
enzymes that leads to the pancreatic damage 
 
3.Ethanol is increasing  the protein content of pancreatic juice, decreasing the 
bicarbonate levels, and the trypsin inhibitor concentration. Ethonal induces The 
formation of protein plugs may also lead an obstructive element to pancreatic 
outflow. 
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IATROGENIC 
1.Many procedures can lead to acute pancreatitis, CBD exploration and 
exploration ampulla of Vater, distal gastrectomy, splenectomy, 
colectomy, nephrectomy, aortic aneurysmorraphy, and retroperitoneal 
lymphadenectomy.  
2. cardio-pulmonary bypass or cardiac transplant can lead to ischaemic 
pancreatitis due to hypoperfusion 
 
3.Aute pancreatitis may occur after ERCP. The risk of post-ERCP acute 
pancreatitis is increased if the contrast agent is infused repeatedly under high 
pressure  and the patients with sphincter of Oddi dysfunction 
HEREDITARY PANCREATITIS 
Hereditary pancreatitis (HP) is an inflammation of the pancreas, attributed to 
genetic causes. It was first described in 1952 by Comfort and Steinbergbut it 
was not until 1996 that Whitcomb et alisolated the first responsible mutation in 
the trypsinogen gene (PRSS1) on the long arm of chromosome seven 
(7q35).these mutations are rarely identified in general screens of patients with 
idiopathic disease and the phenotype of p.R122H and p.N29I is now well 
characterised with the p.A16V mutation recently characterised for the first time. 
There are many other rare mutations or polymorphisms of PRSS1 which remain 
less well understoodand not all HP families have had the responsible genetic 
mutation identified. 
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TUMOURS 
 Pancreatic tumours may produce acute pancreatitis . acute pancreatitis can be 
the first clinical manifestation of the tumor. If the etiology can not be identified 
in acute pancreatitis ,cross sectional imaging should be done to rule out 
pancreatic tumours 
 
 
HYPERLIPIDEMIA 
Patients with types I and V hyperlipoproteinemia are frequently developing 
acute pancreatitis and often it is occurring  in association with the marked 
hypertriglyceridaemia. Toxic fatty acids have been released into the circulation 
because of lipases leads to the impairement in the microcirculation can cause 
acute pancreatitis 
 
 
OTHERS 
1.  several drugs are causing acutepancreatitis. These include the thiazide 
diuretics, furosemide,estrogens, azathioprine, l-asparaginase, 6-mercaptopurine, 
methyldopa, the sulfonamides, tetracycline, pentamidine, procainamide, 
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nitrofurantoin, dideoxyinosine, valproic acid, andacetylcholinesterase inhibitors. 
lipid-based intravenous drugs and solutions, such as propofol, can also cause 
acute pancreatitis. 
 2.hyperparathyroidism  causes  hypersecretion and the formation of calcified 
stones in the duct and parenchyma of the pancreas can produce both the acute & 
chronic pancreatitis 
3.  Ascaris lumbricoides and the liver fluke Clonorchis sinensis infestations are 
causing  Oriental cholangitis, which is associated with cholangiocarcinoma 
which leads to the  obstruction the pancreatic duct. 
 
 
4.azotemia, vasculitis, and the sting of the Trinidadian scorpion Tityus trinitatis. 
massive production of pancreatic juice occurs because of the This scorpion’s 
venom   that causesneurotransmitter discharge from cholinergic nerve terminals, 
leading to pancreatitis.  Antiacetylcholinesterase poisoning also causing the 
same  effect laeding to the acute pancreatitis.if no cause has been identified in 
the course of evaluation it will be called as idiopathic pancreatitis. 
PATHOPHSIOLOGY 
Pancreatitis begins with the activation of digestive zymogens inside acinar cells, 
which cause acinar cell injury.severity of pancreatitis may be determined by the 
Inflammatory cell recruitment and activation, as well as generation and release 
of cytokines and other chemical mediators of inflammation 
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Precipitating Initial Event 
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PATHOPHYSIOLOGY OF ACUTE PANCREATITIS 
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                                  ACINAR CELL EVENTS 
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SYSTEMIC EVENTS 
Acute pancreatitis (AP) is an inflammatory condition of the pancreas that 
involves peripancreatic tissue and remote organs. Excessive systemic 
inflammatory response syndrome (SIRS) in AP leads to distant organ 
damage and multiple organ dysfunction syndrome (MODS), which is the 
primary cause of morbidity and mortality in this condition. Mild AP is self 
limiting but up to 25% of the patients suffer a severe attack and around 30% 
of these will die. 9 
 
 
Approximately half of the deaths in AP occur within the first 2 wk of illness 
and are generally attributed to organ failure. The rest of the deaths occur 
weeks to months later, characterized by extensive retroperitoneal pancreatic 
necrosis and septicemia. AP involves a complex cascade of events 
initializing in pancreatic acinar cells. An unknown trigger within the 
pancreas leads to conversion of digestive proenzymes into their active form, 
initiating auto digestion of the gland causing hemorrhage, necrosis, edema 
and complete destruction of pancreatic parenchyma. Intrapancreatic 
activation of trypsinogen by lysosomal hydrolases is an early triggering 
event in AP.  
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Interestingly both pharmacological and genetic deletion of lysosomal 
hydrolases like cathepsin B can reduce the severity of pancreatitis[7]. Other 
pharmacological agents which block trypsinogen activation can also 
modulate the outcome of AP. 
 
Immune cells involved in elaborating the inflammatory mediators in AP are 
the pancreatic acinar cells, endothelial cells, neutrophils, lymphocytes, 
monocytes and macrophages. Inflammatory mediators believed to participate 
in the pathophysiology of this condition include: tumor necrosis factor-α 
(TNF-α), interleukin-1 (IL-1β), interleukin-6 (IL-6), platelet activating factor 
(PAF), ICAM-1, IL-8, growth related oncogene-a/cytokine-induced 
neutrophils chemo attractant (GRO-α/CINC), monocyte chemotactic protein-
1 (MCP-1), IL-10, complement component C5a, substance P (SP), hydrogen 
sulfide (H2S), and neutral endopeptidase (NEP)[10].  
 
 
In recent years, it has become clear that the signaling molecule nuclear factor 
κB (NF-κB) plays a central role in the initiation and progression of AP[11]. 
The emerging body of evidence suggest that blocking NF-κB activation can 
markedly reduce the severity of AP[12,13]. These findings have opened a 
window of opportunity for the use of selective NF-κB inhibitors in 
regulating the inflammatory process in AP. 11 
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The expression levels of various proinflammatory mediators like TNF-α and 
IL-1β in AP are positively regulated by NF-κB[14,15]. Systemic 
amplification of AP is associated with excessive release of these 
inflammatory mediators from local tissue and systemically. 
 
 This systemic amplification is responsible for most of the mortality 
associated with AP[16]. Studies indicate that both pancreatic and extra 
pancreatic (lung, liver, monocytes, macrophages and endothelial cells) 
activation of NF-κB is associated with development of MODS in AP[17,18]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 28 
 
 
 
 
SYSTEMIC EVENTS IN ACUTE PANCREATITIS 
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DIAGNOSIS  
 CRITERIAS 
 acute onset of a severe constant epigastric pain which often 
radiates through to the mid back)  
 elevation of serum amylase or lipase (>3 times upper limit of normal).  
 Imaging (usually by contrast enhanced CT scanning) is only required 
for the diagnosis of acute pancreatitis when these diagnostic criteria  
are met 
The serum amylase concentration increases almost immediately with the onset 
of disease and peaks within several hours. It remains elevated for 3 to 5 days 
before returning to normal. There is no significant correlation between the 
magnitude of serum amylase elevation and severity of pancreatitis; in fact, a 
milder form of acute pancreatitis is often associated with higher levels of serum 
amylase compared with that in a more severe form of the disease. 
severe form of the disease. 
Hyperamylasemia can also occur as a result of conditions not involving 
pancreatitis. For example, hyperamylasemia can occur in a patient with small 
bowel obstruction, perforated duodenal ulcer, or other intra-abdominal 
inflammatory conditions. In contrast, a patient with acute pancreatitis 
may have a normal serum amylase level, which could be due to several reasons. 
In patients with hyperlipidemia, values might appear to be normal because of 
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interference by lipids with chemical determination of serum amylase. In many 
cases, urinary clearance of pancreatic enzymes from the circulation increases 
during pancreatitis; therefore, urinary levels may be more sensitive than serum 
levels. For these reasons, it is recommended that amylase concentrations also be 
measured in the urine. Urinary amylase levels usually remain elevated for 
several days after serum levels have returned to normal. In patients with severe 
pancreatitis associated with significant necrotic damage, the pancreas may not 
release large amounts of enzymes into the circulation. With increasing severity 
of disease, the intravascular fluid loss may become life-threatening as a result of 
sequestration of edematous fluid in the retroperitoneum. Hemoconcentration 
then results in an elevated hematocrit. However, there also may be 
bleeding into the retroperitoneum or the peritoneal cavity86. In some patients 
(about 1%), the blood from necrotizing pancreatitis may dissect through the soft 
tissues and manifest itself as a bluish discoloration around the umbilicus 
(Cullen’s sign) or in the flanks(Grey Turner’s sign)14. The severe fluid loss may 
lead to prerenal azotemia with elevated blood urea nitrogen and creatinine 
levels. There also may be hyperglycemia, hypoalbuminemia, and hypocalcemia 
sufficient in some cases to produce tetany 
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SEVERITY ASSESSMENT 
 Predicting acute pancreatitis severity is important in making triage  and in 
making decisions about fluid therapy, whether an ERCP is indicated, 
and other issues.  the most widely used being the Ranson’s criteria  or modified 
Glasgow criteria. Both use clinical and biochemical parameters scored over the 
first 48 hours of admission. When there are 3 or more positive criteria, the 
disease is considered“predicted severe.” There are many other approaches to 
predicting severity. At 24 hours after admission an APACHE II score of 8 or 
more or a serum C-reactive protein level of >150mg/dl has a similar accuracy in 
predicting severity as Ranson’s criteria.  The more recently proposed Bedside 
Index for Severity of Acute Pancreatitis (BISAP) is calculated from blood urea 
nitrogen (> 25 mg/dl), impaired mental status (GCS <15), presence of systemic 
inflammatory response syndrome (SIRS), age >60 years, and pleural effusion.   
 
Another approach has been taken in seeking to predict those with ‘harmless’ 
acute pancreatitis using three factors that can be determined on admission; 
absence of rebound tenderness or guarding, normal hematocrit, and normal 
serum creatinine. The accuracy of this approach appears to be over 90%, and 
triages most patients with acute pancreatitis away from intensive care. 
 
 
 32 
 
 
CLASSIFICATION OF SEVERITY OF ACUTE PANCREATITIS 
A four-category classification of severity 
 mild, 
  moderate, 
 severe,  
 critical) . 
 The key determinants of severity are local complications 
 absent, 
  sterile or  
 infected)  
       and  systemic complications (absent, transient organ failure, or persistent 
organ failure).  
FOUR CATEGORIES OF ACUTE PANCREATITIS BASED ON 
ORGAN FAILURE & LOCAL COMPLICATIONS 
DETERMINANTS NO LOCAL 
COMPLICATIONS 
STERILE LOCAL 
COMPLICATIONS 
INFECTED 
LOCAL 
COMPLICATIONS 
NO ORGAN 
FAILURE 
MILD MODERATE SEVERE 
TRANSIENT 
ORGAN 
FAILURE  
MODERATE MODERATE SEVERE 
PERSISTENT 
ORGAN 
FAILURE 
SEVERE SEVERE CRITICAL 
RANSON’S SCORE FOR NON GALLSTONE PANCREATITIS 
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BOX 56-1 Ranson’s Prognostic Criteria for Non gallstone 
Pancreatitis 
At presentation 
• Age >55 yr 
• Blood glucose level >200 mg/dL 
• WBC >16,000 cells/mm3 
• Lactate dehydrogenase level >350 IU/L 
• Aspartate aminotransferase >250 IU/L 
After 48 hours of admission 
• Hematocrit*: Decrease >10% 
• S erum calcium level <8 mg/dL 
• Base deficit >4 mEq/L 
• Blood urea nitrogen level†: Increase >5 mg/dL 
• Fluid requirement >6 liters 
• Pao2 <60 mm Hg 
Ranson score ≥3 defines severe pancreatitis.*As compared with admission 
value. 
 
RANSON’S SCORE FOR  GALLSTONE PANCREATITIS 
At presentation 
• Age >70 yr 
• Blood glucose level >220 mg/dL 
• WBC >18,000 cells/mm3 
• Lactate dehydrogenase level >400 IU/liter 
• Aspartate aminotransferase level >250 IU/liter 
After 48 hours of admission 
• Hematocrit*: Decrease >10% 
• S erum calcium level <8 mg/dL 
• Base deficit >5 mEq/L 
• Blood urea nitrogen level†: Increase >2 mg/dL 
• Fluid requirement >4 liters 
• Pao2: Not available 
Ranson score ≥3 defines severe pancreatitis. 
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APACHE II SCORING SYSTEM 
AP severity can also be addressed using the Acute Physiology and Chronic 
Health Evaluation (APACHE II) score. Based on the patient’s age, previous 
health status, and 12 routine physiologic measurements, APACHE II provides a 
general measure of the severity of disease. An APACHE II score of 8 or higher 
defines severe pancreatitis. The main advantage is that it can be used on 
admission and repeated at any time. However, it is complex, not specific for 
AP, and based on the patient’s age, which easily upgrades the AP severity score. 
 
ATLANTA’S CRITERIA FOR ACUTE PANCREATITIS 
 
Organ Failure As Defined 
Shock (systolic blood pressure <90 mm Hg) 
Pulmonary insufficiency (PaO2 <60 mm Hg) 
Renal failure (creatinine level >2 mg/dL after fluid 
resuscitation) 
GI bleeding (>500 mL/24 hr) 
Systemic Complications 
Disseminated intravascular coagulation (platelet count 
≤100,000) 
Fibrinogen <1 gr/L 
Fibrin split products >80 μg/dL 
Metabolic disturbance (calcium level ≤7.5 mg/dL) 
Local Complications 
Necrosis 
Abscess 
Pseudocyst 
 
Severe pancreatitis is defined by the presence of any evidence of organ failure 
or a local complication. 
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BISAP SCORE 
the Bedside Index of Severity in Acute Pancreatitis incorporates five clinical 
and laboratory parameters obtained within the first 24 hours of hospitalization . 
Presence of three or more of these factors was associated with substantially 
increased risk for in-hospital mortality among patients with acute pancreatitis.  
 
 
 
 
PARAMETERS 
SCORE 
         1          0 
Blood Urea 
Nitrogen 
>25 mg% <25 mg% 
Impared mental status present Absent 
Age >60 <60 
SIRS 2/4 present Absent 
Pleural effusion present Absent 
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CRITERIA FOR SIRS 
 
 
 
 
CT SEVERITY INDEX 
• Temperature > 38 0 C or <36 
• Pulse > 90/minute 
• Tachypnea > 24/minute 
• WBC > 12000/mm 
Any two of four will be significant if present 
simultaneously. 
A score of > 3 will indicate pancreatitis (early organ failure/ pancreatic 
necrosis) 
FEATURE  POINTS 
PANCREATIC INFLAMMATION 
Normal pancreas              0 
Focal or diffuse pancreatic 
enlargement 
             1 
Intrinsic pancreatic alterations  ith 
peripancreatic fat inflammatory 
changes  
             2 
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INTERPRETATION 
Points severity morbitidy Mortality 
   0 to 3 mild     3 %       8 % 
   4 to 6 moderate     6%        35% 
    7 to 10 severe     17%         92% 
 
 
 
Single fluid collection / or phlegmon              3 
Two or more  fluid collections or 
gas ,in or adjacent to the pancreas 
             4 
Pancreatic necrosis 
None                0 
Less than 30 %               2 
30 to 50 %               4 
>50 %               6 
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COMPLICATIONS 
Sterile and Infected Peripancreatic Fluid Collections 
The presence of acute abdominal fluid during an episode of AP has been 
described in 30% to 57% of patients.3 In contrast to pseudocysts and cystic 
neoplasias of the pancreas, fluid collections are not surrounded or encased by 
epithelium or fibrotic capsule. The presence of fever, elevated white blood cell 
(WBC) count, and abdominal pain suggest infection of this fluid and 
percutaneous aspiration is confirmatory. Percutaneous drainage and IV 
administration of antibiotics should be instituted  if infection is present 
 
 
 
 
 
 
 
 
 
 
 
 
                           Peripancreatic fluid collection 
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Pancreatic Necrosis and Infected Necrosis 
Pancreatic necrosis is the presence of nonviable pancreatic parenchyma 
or peripancreatic fat; it can present as a focal area or diffuse involvement of the 
gland. Contrast-enhanced CT is the most reliable technique to diagnose 
pancreatic necrosis. It istypically seen as areas of low attenuation (<40 to 50 
HU) after the injection of IV contrast. Normal parenchyma usually has a density 
of 100 to 150 HU.9 Up to 20% of patients with AP develop pancreatic necrosis. 
It is important to identify and provide proper treatment of this complication 
because most who develop multiorgan failure have necrotizing pancreatitis; 
pancreatic necrosis has been documented in up to 80% of the autopsies of 
patients who died after an episode of AP.4 The main complication of pancreatic 
necrosis is infection. The risk is directly related to the amount of necrosis; in 
patients with pancreatic necrosis involving less than 30% of the gland, 
the risk of infection is 22%. The risk is 37% for patients with pancreatic 
necrosis that involves 30% to 50% of the gland and up to 46% if more than 70% 
of the gland is affected.4 This complication is associated with bacterial 
translocation usually involving enteric flora, such as gram-negative rods (e.g., 
Escherichia coli, Klebsiella and Pseudomonas spp.) and Enterococcus spp. 
Infected pancreatic necrosis should be suspected in patients with prolonged 
fever, elevated WBC count, or progressive clinical deterioration. Evidence of 
air within the pancreatic necrosis seen on a CT scan confirms the diagnosis but 
is a rare finding. If infected necrosis is suspected, fine-needle aspiration (FNA) 
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should be performed. Once infection has been demonstrated, IV antibiotics 
should be given. Because of their penetration into the pancreas and spectrum 
coverage, carbapenems are the first option of treatment. Alternative therapy 
includes quinolones, metronidazole,third-generation cephalosporins, and 
piperacillin. Definitive treatment for infected pancreatic necrosis is surgical 
débridement with necrosectomy, closed continuous irrigation, 
and open packaging . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute pancreatitis with infected necrosis 
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Pancreatic Pseudocysts 
Pancreatic pseudocysts occur in 5% to 15% of patients who have peripancreatic 
fluid collections after AP. By definition, the capsule of a pseudocyst is 
composed of collagen and granulation tissue and it is not lined by 
epithelium.The fibrotic reactiontypically requires at least 4 to 8 weeks to 
develop. Up to 50% of patients with pancreatic pseudocysts will develop 
symptoms. The presence of persistent pain, early satiety, nausea, weight loss, 
and elevated pancreatic enzyme levels in plasma suggest this diagnosis. The 
diagnosis is corroborated with by CT or MRI. EUS with FNA is indicated for 
patients in whom the diagnosis of pancreatic pseudocyst is not clear. 
Characteristic features of pancreatic pseudocysts include high amylase levels 
associated with the absence of mucin and low carcinoembryonic antigen (CEA) 
levels 
Observation is indicated for asymptomatic patients because spontaneous 
regression has been documented in up to 70% of cases; this is particularly true 
for patients with pseudocysts smaller than 4 cm in diameter, located in the tail, 
and no evidence of pancreatic duct obstruction or communication with the main 
pancreatic duct.Invasive therapies are indicated for symptomatic patients or 
when the differentiation between a cystic neoplasm and pseudocyst is not 
possible. Because most patients are treated with decompressive procedures and 
not with resection, it is imperative to have a pathologic diagnosis. Surgical 
drainage has been the traditional approach for pancreatic pseudocysts.16 
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Transgatric and transduodenal endoscopic drainage are safe and effective 
approaches for patients with pancreatic pseudocysts in close contact (defined as 
<1 cm) with the stomach and duodenum, respectively. In addition,transpapillary 
drainage can be attempted in pancreatic pseudocysts communicating with the 
main pancreatic duct. For patients in whom a pancreatic duct stricture is 
associated with a pancreatic pseudocyst, endoscopic dilation and stent 
placement are indicated 
Surgical drainage is indicated for patients with pancreatic pseudocysts that 
cannot be treated with endoscopic techniques and patients who fail endoscopic 
treatment. Definitive treatment depends on the location of the cyst. Pancreatic 
pseudocysts closely attached to the stomach should be treated with a 
cystgastrostomy. Pancreatic pseudocysts located in the head of the pancreas that 
are in close contact with the duodenum are treated with a cystoduodenostomy. 
Finally, some pseudocysts are not in contact with the stomach or duodenum. 
The surgical treatment for these patients is a Roux-en-Y cystojejunostomy.  
Complications of pancreatic pseudocysts include bleeding and 
pancreaticopleural fistula secondary to vascular and pleural erosion, 
respectively, bile duct and duodenal obstruction, rupture into the abdominal 
cavity, and infection. Percutaneous drainageis only indicated for septic patients 
secondary to pseudocyst infection because it has a high incidence of external 
fistula. 
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PANCREATIC PSEUDOCYST 
 
 
Pancreatic Ascites and Pancreaticopleural Fistulas  
 complete disruption of the pancreatic duct can lead to significant accumulation 
of, fluid. This condition should be suspected in patients who have an episode of 
AP, develop significant abdominal distention, and have free intraabdominal 
fluid. Diagnostic paracentesis typically demonstrates elevated amylase and 
lipase levels. Treatment consists of abdominal drainage combined with 
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endoscopic placement of a pancreatic stent across the disruption. Failure of this 
therapy requires surgical treatment; it consists of distal resection and 
closure of the proximal stump. Pancreatico pleural fistula is rare. Symptoms that 
suggest this condition include dyspnea, abdominal pain, cough, and chest pain. 
The diagnosis is confirmed with chest x-ray, thoracentesis, and CT scan.  
Amylase levels above 50,000 IU in the pleural fluid confirm the diagnosis. It is 
more common after alcoholic pancreatitis and, in 70% of patients, is associated 
with pancreatic pseudocysts. Initial treatment requires chest drainage, parenteral 
nutritional support, and administration of octreotide. Up to 60% of patients 
respond to this therapy. Persistent drainage should also be treated with 
endoscopic sphincterotomy and stent placement. Patients who do not respond to 
these measures require surgical treatment, similar to that described for 
pancreatic ascites.17 
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Pancreaticopleural fistula (arrows) detected with the second CT 
examination, which was performed after the thoracocentesis: (A) axial 
image, (B) coronal reconstruction, (C) sagittal reconstructionS 
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Vascular Complications 
Acute pancreatitis is rarely associated with arterial vascular complications. 
The most common vessel affected is the splenic artery, but the superior 
mesenteric, cystic, and gastroduodenal arteries have also been found to be 
affected. It has been proposed that pancreatic elastase damages the vessels, 
leading to pseudoaneurysm formation. Spontaneous rupture results in massive 
bleeding. Clinical manifestations include sudden onset of abdominal pain, 
tachycardia, and hypotension. If possible, arterial embolization should be 
attempted to control the bleeding. Refractory cases require ligation of the vessel 
affected. The mortality ranges from 28% to 56%. Pancreatic inflammation can 
also produce vascular thrombosis; the vessel usually affected is the splenic vein 
but, in severe cases, it can extend into the portal venous system.  
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CT angiography depicting an 8.6-cm partially thrombosed splenic artery 
pseudoaneurysm at the pancreatic tail and a subcapsular splenic fluid 
collection. 
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Pancreatocutaneous Fistula 
The frequency of pancreatic fistulas is rare However, the incidence of these 
complications increases in patients with other complications after AP in patients 
with pancreatic pseudocysts  and  in patients with infected necrosis after 
surgical débridement.Treatment is conservative for most patients. 
 
 
 
 
 
 
 
 
 
 
 
 
PANCREATICO CUTANEOUS & PANCREATICO ENTERIC FIST 
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                       OBSERVATION AND DISCUSSION 
 
 it is a randamised control study 
 
 this review describes the beneficial effects of early enteral feeding in 
acute pancreatitis 
 
 relevant literature analysed in the view points of early enteral vs 
parenteral feeding in acute pancreatitis 
 
 latest meta analyses suggest that enteral nutrition significantly reduces the 
morbitidies and mortality in acute pancreatitis compared to parentral 
feeding 
 
 to maintain the gut barrier function and to prevent the early bacterial 
translocation,early enteral feeding commenced with in 24-48 hours of 
admission 
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In st 
 
  
 IN MY STUDY MOST COMMONEST AGE GROUP IS 31 – 40 
YEARS,WHICH IS 61.7 % OF MY POPULATION 
 LEAST COMMONEST AGE GROUP IS ABOVE 50,WHICH IS 
6.7 % OF MY POPULATION 
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  IN MY STUDY THE MOST COMMONEST SEX AFFECTED IS MALE (98.3 % ) 
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 IN MY STUDY THE MOST COMMONEST SEX AFFECTED IS MALE (98.3 % ) 
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 THE MOST COMMONEST CAUSE OF PANCREATITIS IN MY STUDY 
POPULATION IS ALCOHOL ( 90% ) 
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 Total no of mild severity cases in my study population are 23 (38.3%),in 
which the cases are 14 (46.7% of mild cases) controls 9 (30% of mild 
cases).Total no of moderate cases in my study population are 37 (61.7 
%).inwhich the cases are 16 (53.3 %) and controls are 21 (70 % ) 
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 Totally 6 cases are affected by non infective complications ( 10% of total 
population ).in which 2 cases (6.7 % of cases ) & 4 controls (13.3 % of 
controls) 
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 Totally 22 cases were affected by non pancreatitis complications.in 
which 5 cases (16.7 % of  cases),17 controls (56.7 % of controls ) 
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 IN MY STUDY MOST COMMONEST AGE GROUP IS 31 – 40 
YEARS,WHICH IS 61.7 % OF MY POPULATION 
 LEAST COMMONEST AGE GROUP IS ABOVE 50,WHICH IS 
 6.7 % OF MY POPULATION 
 
  
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 The average length of hospital stay in cases -6.43 days 
The average length of hospital stay in controls- 10.48 days 
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 T-Test      
       
       
 CC N Mean 
Std. 
Deviation 
Std. Error 
Mean 
 
AGE Cases 30 39 9.380 1.712 
 
Controls 30 35 4.056 .741 
 
STAY Cases 30 6 2.873 .525 
 
Controls 30 11 3.199 .584 
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Independent Samples Test 
  
t-test for Equality of Means 
t df 
Sig. (2-
tailed) 
AGE   2.162 58 .035 
STAY   -5.562 58 .000 
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CC 
Total  Cases Controls 
 
SEX F Count 1 0 1 
 
% within 
CC 
3.3% 0.0% 1.7% 
 
M Count 29 30 59 
 
% within 
CC 
96.7% 100.0% 98.3% 
 
Total Count 30 30 60 
 
% within 
CC 
100.0% 100.0% 100.0% 
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   Value df 
Asymp. 
Sig. (2-
sided) 
Exact 
Sig. (2-
sided) 
Exact Sig. 
(1-sided) 
 
Pearson Chi-
Square 
1.017a 1 .313     
 
Continuity 
Correctionb 
0.000 1 1.000     
 
Likelihood 
Ratio 
1.403 1 .236     
 
Fisher's Exact 
Test 
      1.000 .500 
 
N of Valid 
Cases 
60         
 
a. 2 cells (50.0%) have expected count less than 5. The minimum expected 
count is .50. 
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CC 
Total  Cases Controls 
 
CAUSE ALCOHOL Count 26 28 54 
 
% 
within 
CC 
86.7% 93.3% 90.0% 
 
CHOLELITHiASIS Count 0 1 1 
 
% 
within 
CC 
0.0% 3.3% 1.7% 
 
DRUG INDUCED Count 1 0 1 
 
% 
within 
CC 
3.3% 0.0% 1.7% 
 
GALL STONES Count 1 0 1 
 
% 
within 
CC 
3.3% 0.0% 1.7% 
 HPER CALCAEMIA Count 1 0 1 
 
% 
within 
CC 
3.3% 0.0% 1.7% 
 MALIGNANCY Count 1 0 1 
 
% 
within 
CC 
3.3% 0.0% 1.7% 
 POST ERCP 
PANCREATITIS 
Count 0 1 1 
 
% 
within 
CC 
0.0% 3.3% 1.7% 
 Total Count 30 30 60 
 
% 
within 
CC 
100.0% 100.0% 100.0% 
 65 
 
 
 
 
 
 
 
 
 Cases Controls 
 
ALCOHOL 86.7% 93.3% 
 
CHOLELITHiASIS 0.0% 3.3% 
 
DRUG INDUCED 3.3% 0.0% 
 
GALL STONES 3.3% 0.0% 
 
HPER CALCAEMIA 3.3% 0.0% 
 
MALIGNANCY 3.3% 0.0% 
 
POST ERCP PANCREATITIS 0.0% 3.3% 
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Chi-Square Tests 
 
 
   Value df 
Asymp. Sig. 
(2-sided) 
 
Pearson 
Chi-Square 
6.074a 6 .415 
 
Likelihood 
Ratio 
8.392 6 .211 
 
N of Valid 
Cases 
60     
 
a. 12 cells (85.7%) have expected count less than 
5. The minimum expected count is .50. 
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CC 
Total  Cases Controls 
 DISEASE SEVERITY MILD Count 14 9 23 
 
% 
within 
CC 
46.7% 30.0% 38.3% 
 MODERATE Count 16 21 37 
 
% 
within 
CC 
53.3% 70.0% 61.7% 
 Total Count 30 30 60 
 
% 
within 
CC 
100.0% 100.0% 100.0% 
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 Chi-Square Tests 
   Value df 
Asymp. 
Sig. (2-
sided) 
Exact 
Sig. 
(2-
sided) 
Exact Sig. 
(1-sided) 
 
Pearson Chi-Square 1.763a 1 .184     
 
Continuity Correctionb 1.128 1 .288     
 
Likelihood Ratio 1.773 1 .183     
 
Fisher's Exact Test       .288 .144 
 
N of Valid Cases 60         
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CC 
Total  Cases Controls 
 NON INFECTIVE 
COMPLICATIONS 
NO Count 28 26 54 
 
% 
within 
CC 
93.3% 86.7% 90.0% 
 YES Count 2 4 6 
 
% 
within 
CC 
6.7% 13.3% 10.0% 
 Total Count 30 30 60 
 
% 
within 
CC 
100.0% 100.0% 100.0% 
 Cases Controls 
No 
93.3% 86.7% 
Yes 
6.7% 13.3% 
  Value df 
Asymp. 
Sig. (2-
sided) 
Exact 
Sig. (2-
sided) 
Exact Sig. 
(1-sided) 
Pearson 
Chi-Square 
.741a 1 .389     
Continuity 
Correctionb 
.185 1 .667     
Likelihood 
Ratio 
.754 1 .385     
Fisher's 
Exact Test 
      .671 .335 
N of Valid 
Cases 
60         
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CASES 
  
   CONTROLS 
  
                NO 
 
         83.3 % 
 
        43.3 % 
 
 
              YES 
  
   
         16.7 % 
 
 
        66.7 % 
  
  
   
 
 
 
  
CC 
Total  Cases 
Control
s 
 
NON 
PANCREATITIS 
COMPLICATION
S 
NO Count 25 13 38 
 
% 
withi
n CC 
83.3% 43.3% 63.3% 
 
 
YE
S 
 
 
 
Count 
     
 5 
 
17 
 
22 
 
% 
withi
n CC 
 
16.7% 
 
56.7% 
 
36.7% 
 
 
 
 
Total 
 
 
 
Count 
 
 
 
30 
 
 
 
30 
 
 
 
60 
 
% 
withi
n CC 
100.0% 100.0% 100.0% 
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 Cases Controls 
Upto 30 yrs 20.0% 23.3% 
31 - 40 yrs 50.0% 73.3% 
41 - 50 yrs 16.7% 3.3% 
Above 50 yrs 13.3%   
 
 
 
Chi-Square Tests 
   Value df 
Asymp. 
Sig. (2-
sided) 
Exact 
Sig. 
(2-
sided) 
Exact 
Sig. 
(1-
sided) 
 
Pearson Chi-Square 10.335a 1 .001     
 
Continuity Correctionb 8.684 1 .003     
 
Likelihood Ratio 10.771 1 .001     
 
Fisher's Exact Test       .003 .001 
 
N of Valid Cases 60         
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Crosstab 
 
  
CC 
Total  Cases Controls 
 
AGE Upto 
30 yrs 
Count 6 7 13 
 
% 
within 
CC 
20.0% 23.3% 21.7% 
 
31 - 
40 yrs 
Count 15 22 37 
 
% 
within 
CC 
50.0% 73.3% 61.7% 
 
41 - 
50 yrs 
Count 5 1 6 
 
% 
within 
CC 
16.7% 3.3% 10.0% 
 
Above 
50 yrs 
Count 4 0 4 
 
% 
within 
CC 
13.3% 0.0% 6.7% 
 
Total Count 30 30 60 
 
% 
within 
CC 
100.0% 100.0% 100.0% 
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   Value df 
Asymp. 
Sig. (2-
sided) 
 
Pearson Chi-
Square 
8.068a 3 .045 
 
Likelihood 
Ratio 
9.866 3 .020 
 
Linear-by-
Linear 
Association 
4.750 1 .029 
 
N of Valid 
Cases 
60     
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 RESULTS & CONCLUSIONS 
AGE 
 In my study , the total population is 60 
 Cases – 30 & controls – 30. The mean age of case group is 39 & the mean 
age of control group is 35. 
 Regarding distribution 13 patients are upto 30 years of age ( 21.7 % of 
population).in which 6 cases (20 % of cases ) &  7 controls ( 23.3 % of 
controls) Confined to this group 
 37 patients  (61.7 % ) of study population fall between 31 – 40 years 
.inwhich 15 cases (50 % of cases) & 22 controls (73.3 % of controls) 
confined to this group 
 6 patients fall between 41 – 50 years  (10 % of population).in which 5 
cases (16.7 % of cases ) & 1 control (3.3% of controls ) confined to this 
group 
 4 (6.7% of population )patients fall  in above 50 group.in which 4 
controls (13.3 % of controls ) confined to this group 
 IN MY STUDY MOST COMMONEST AGE GROUP IS 31 – 40 
YEARS,WHICH IS 61.7 % OF MY POPULATION 
 LEAST COMMONEST AGE GROUP IS ABOVE 50,WHICH IS 
 6.7 % OF MY POPULATION 
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SEX 
 In the total population of 60, only one case was female , 
females in my study is 1.7 % & males are 98.3 % 
 
 
 IN MY STUDY THE MOST COMMONEST SEX 
AFFECTED IS MALE (98.3 % ) 
 
 
 
 
CAUSES  
 Total no of patients affected by alcohol in my study population are 54 & 
it is  90 %  of my population , followed by cholelithiasis (3.3 %) 
,hpercalcaemia  (1.7 %),malignancy (1.7 % )& post ERCP (1.7 %). 
 
 
 
 THE MOST COMMONEST CAUSE OF PANCREATITIS IN MY 
STUDY POPULATION IS ALCOHOL ( 90% ) 
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DISEASE SEVERITY 
 
 Total no of mild severity cases in my study population are 23 (38.3%),in 
which the cases are 14 (46.7% of mild cases) controls 9 (30% of mild 
cases).Total no of moderate cases in my study population are 37 (61.7 
%).inwhich the cases are 16 (53.3 %) and controls are 21 (70 % ) 
 
 
 THERE IS NO STATISTICALLY SIGNIFICANT DIFFERENCE 
BETWEEN CASES & CONTROLS IN DISEASE SEVERITY 
 
NON INFECTIVE COMPLICATIONS 
 Totally 6 cases are affected by non infective complications ( 10% of total 
population ).in which 2 cases (6.7 % of cases ) & 4 controls (13.3 % of 
controls) 
 
 INCIDENCE OF NON-INFECTIVE COMPLICATIONS IS HIGER 
IN CONTROL GROUPS THAN CASES 
 
 THERE IS NO STATISTICALLY SIGNIFICANT DIFFERENCE 
IN INCIDENCENCE OF NON INFECTIVE COMPLICATIONS 
BETWEEN CASES & CONTROLS 
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NON PANCREATITIS COMPLICATIONS 
 Totally 22 cases were affected by non pancreatitis complications.in which 
5 cases (16.7 % of  cases),17 controls (56.7 % of controls ) 
 
 INCIDENCE OF NON PANCREATITIS COMPLICATIONS IS 
HIGHER IN CONTROL GROUP THAN THE CASE 
 THERE IS A STATISTICALLY SIGNIFICANT DIFFERENCE IN 
NON PANCREATITIS COMPLICATIONS BETWEEN CASES & 
CONTROLS 
HOSPITAL STAY 
The average length of hospital stay in cases -6.43 days 
The average length of hospital stay in controls- 10.48 days 
 
 THERE IS A STATISTICALLY SIGNIFICANT DIFFERENCE IN 
LENGTH OF HOSPITAL STAY BETWEEN CASES & 
CONTROLS 
 
 
 
 
 
 
 78 
 
                                BIBLIOGRAPHY 
 
1 . Peery AE , Dellon ES , Lund J et al. Burden of gastrointestinal diseases in 
the United States: 2012 Update . Gastroenterology 2012 ; 143 : 1179 – 87 . 
2 . Fagenholz PJ , Fernandez-del Castillo C , Harris NS et al. Direct medical 
costs of acute pancreatitis hospitalizations in the United States . Pancreas 
2007 ; 35 : 302 – 7 . 
3 . Fagenholz PJ , Castillo CF , Harris NS et al. Increasing United States 
hospitaladmissions for acute pancreatitis, 1988-2003 . Ann Epidemiol 2007 ; 17 
: 491 – 7 . 
4 . Yadav D , Lowenfels AB . Trends in the epidemiology of the fi rst attack of 
acute pancreatitis: a systemic review . Pancreas 2006 ; 33 : 323 – 30 . 
5 . Bradley EL . A clinically based classifi cation system of acute pancreatitis . 
Arch Surg 1993 ; 128 : 586 – 90 . 
6 . Banks PA , Bollen TL , Dervenis C et al. Classifi cation of acute pancreatitis 
— 2012: revision of Atlanta classifi cation and defi nitions by international 
consensus . Gut 2013 ; 62 : 102 – 11 . 
7 . Busquets J , Fabregat J , Pelaez N et al. Factors infl uencing mortality in 
patients undergoing surgery for acute pancreatitis: importance of peripancreatic 
tissue and fl uid infection . Pancreas 2013 ; 42 : 285 – 92 . 
 
 
 79 
 
8 . Marshall JC , Cook DJ , Christou NV et al. Multiple organ dysfunction 
score: a reliable descriptor of complex clinical outcome . Crit Care Med 
1995 ; 23 : 1638 – 52 . 
9 . Wall I , Badalov N , Baradarian R et al. Decreased morbidity and mortality 
in patients with acute pancreatitis related to aggressive intravenous hydration . 
Pancreas 2011 ; 40 : 547 – 50 . 
10 . Gardner TB , Vege SS , Pearson RK et al. Fluid resuscitation in acute 
pancreatitis . Clin Gastroenterol Hepatol 2008 ; 6 : 1070 – 6 . 
11 . Guyatt GH , Oxman AD , Vist GE et al. GRADE: an emerging consensus 
on rating quality of evidence and strength of recommendations . BMJ 2008 ; 
336 : 924 – 6 . 
12 . Clavien PA , Robert J , Meyer P et al. Acute pancreatitis and 
normoamylasemia. Not an uncommon combination . Ann Surg 1989 ; 210 : 614 
– 20 . 
13 . Winslet M , Hall C , London NJM . Relation of diagnostic serum amylase 
levels to aetiology and severity of acute pancreatitis . Gut 1992 ; 33 : 982 – 6 . 
14 . Malka D , Rosa-Hezode I . Positive and etiological diagnosis of acute 
pancreatitis . Gastroenterol Clin Biol 2001 ; 25 : 1S153 – 1S68 . 
15 . UK guidelines for the management of acute pancreatitis . Gut 2005 ; 54 : 
1 – 9 . 
 
 
 80 
 
16 . Steinberg WM , DeVries JH , Wadden T et al. Longitudinal monitoring of 
lipase and amylase in adults with type 2 diabetes and obesity: Evidence 
from two phase 3 randomized clinical trials with the once-daily GLP-1 
analog liraglutide . Gastroenterology 2012 ; 121 : A246 . 
17 . Shah AM , Eddi R , Kothari ST et al. Acute pancreatitis with normal serum 
lipase: a case series . JOP 2010 ; 11 : 369 – 72 . 
18 . Kiriyama , Gabata T , Takada T et al. New diagnostic criteria of acute 
pancreatitis . J Hepatobiliary Pancreat Sci 2010 ; 17 : 24 – 36 . 
19 . Lippil G , Valentino M , Cervellin G . Laboratory diagnosis of acute 
pancreatitis: 
in search of the Holy Grail . Crit Rev Clin Lab Sci 2012 ; 49 : 18 – 31 . 
20 . Balthazar EJ . Acute pancreatitis: assessment of severity with clinical and 
CT evaluation . Radiology 2002 ; 223 : 603 – 13 . 
21 . Arvanitakis M , Delhaye M , Maertelaere VD et al. Computed tomography 
and MRI in the assessment of acute pancreatitis . Gastroenterology 2004 ; 
126 : 715 – 23 . 
22 . Zaheer A , Singh VK , Qureshi RO et al. Th e revised Atlanta classifi cation 
for acute pancreatitis: updates in imaging terminology and guidelines . 
Abdom Imaging 2013 ; 38 : 125 – 36 . 
23 . Bollen TL , Singh VK , Maurer R et al. Comparative evaluation of the 
modifi ed CT severity index and CT severity index in assessing severity of 
acute pancreatitis . AJR Am J Roentgenol 2011 ; 197 : 386 – 92 . 
 81 
 
24 . Stimac D , Miletic D , Radic M et al. Th e role of non enhanced mangetic 
resonance imaging in the early assessment of acute pancreatitis . Am J 
Gastroenterol 2007 ; 102 : 997 – 1004 . 
25 . Lankisch PG , Assmus C , Lehnick D et al. Acute pancreatitis: does gender 
matter? Dig Dis Sci 2001 ; 46 : 2470 – 4 . 
26 . Gullo I , Migliori M , Olah A et al. Acute pancreatitis in fi ve European 
countries: etiology and mortality . Pancreas 2002 ; 24 : 223 – 7 . 
27 . Lowenfels AB , Maisonneuve P , Sullivan T . Th e changing character of 
acute pancreatitis: epidemiology, etiology, and prognosis . Curr Gastroenterol 
Rep 2009 ; 11 : 97 – 103 . 
28 . Johnson C , L é vy P . Detection of gallstones in acute pancreatitis: when 
and how? Pancreatology 2010 ; 10 : 27 – 32 . 
29 . Moreau JA , Zinsmeister AR , Melton LJ et al. Gallstone pancreatitis and 
the eff ect of cholecystectomy . Mayo Clin Proc 63 ; 466 : 1988 . 
30 . Yadav D , O ’ Connell M , Papachristou GI . Natural history following the 
fi rst attack of acute pancreatitis . Am J Gastroenterol 2012 ; 107 : 1096 – 103 . 
31 . Ammann RW . Th e natural history of alcoholic chronic pancreatitis . Intern 
Med 2001 ; 40 : 368 – 75 . 
32 . Steinberg W , Tenner S . Medical progress: acute pancreatitis . New Engl J 
Med 1994 ; 330 : 1198 – 210 . 
 
 
 82 
 
33 . Rebours V , Vullierme MP , Hentic O et al. Smoking and the course of 
recurrent acute and chronic alcoholic pancreatitis: a dose-dependent 
relationship . Pancreas 2012 ; 41 : 1219 – 24 . 
34 . Whitcomb DC . Genetic polymorphisms in alcoholic pancreatitis . Dig Dis 
Sci 2005 ; 23 : 247 – 54 . 
35 . Badalov N , Baradarian R , Iswara K et al. Drug induced acute pancreatitis: 
an evidence based approach . Clin Gastroenterol Hepatol 2007 ; 101 : 454 – 76 . 
36 . Fortson MR , Freeman SN , Webster PD . Clinical assessment of 
hyperlipidmeic pancreatitis . Am J Gastroenterol 1995 ; 90 : 2134 – 9 . 
37 . Parenti DM , Steinberg W , Kang P . Infectious causes of acute pancreatitis 
.Pancreas 1996 ; 13 : 356 – 71 . 
38 . Farmer RG , Winkelman EI , Brown HB et al. Hyperlipoproteinemia and 
pancreatitis . Am J Med 1973 ; 54 : 161 – 5 . 
39 . Toskes PP . Hyperlipidmic pancreatitis . Gastroenterol Clin North Am 
1990 ; 19 : 783 – 91 . 
40 . Yadav D , Pitchumoni CS . Issues in hyperlipidemic pancreatitis . J Clin 
Gastroenterol 2003 ; 36 : 54 – 62 . 
41 . Simpson WF , Adams DB , Metcalf JS et al. Nonfunctioning pancreatic 
neuroendocrine tumors presenting as pancreatitis: report of four cases . 
Pancreas 1988 ; 3 : 223 – 31 . 
42 . Kohler H , Lankisch PG . Acute pancreatitis and hyperamylasaemia in 
pancreatic carcinoma . Pancreas 1987 ; 2 : 117 – 9 . 
 83 
 
43 . Robertson JF , Imrie CW . Acute pancreatitis associated with carcinoma of 
the ampulla of Vater . Br J Surg 1987 ; 74 : 395 – 7 . 
44 . Bank S , Indaram A . Causes of acute and recurrent pancreatitis. Clinical 
considerations and clues to diagnosis . Gastroenterol Clin North Am 
1999 ; 28 : 571 – 89 , viii . 
45 . Banks PA . Epidemiology, natural history, and predictors of disease 
outcome in acute and chronic pancreatitis . Gastrointest Endosc 2002 ; 56 : 
S226 – 30 . 
46 . Tandon M , Topazian M . Endoscopic ultrasound in idiopathic acute 
pancreatitis . Am J Gastroenterol 2001 ; 96 : 705 – 9 . 
47 . Al-Haddad M , Wallace MB . Diagnostic approach to patients with acute 
idiopathic pancreatitis, what should be done? World J Gastroenterol 
2008 ; 14 : 1007 – 10 . 
48 . DiMagno MJ , Dimagno EP . Pancreas divisum does not cause pancreatitis, 
but associates with CFTR mutations . Am J Gastroenterol 2012 ; 107 : 318 – 20 
. 
49 . Steinberg WM , Chari ST , Forsmark CE et al. Controversies in clinical 
pancreatology: management of acute idiopathic recurrent pancreatitis . 
Pancreas 2003 ; 27 : 103 – 17 . 
50 . Badalov N , Tenner S , Baillie J . Prevention and treatment of post-ERCP 
pancreatitis . JOP 2009 ; 10 : 88 – 97 . 
 84 
 
51 . Cote GA , Imperiale TF , Schmidt SE et al. Similar effi cacies of biliary, 
with or without pancreatic, sphincterotomy in treatment of idiopathic recurrent 
acute pancreatitis . Gastroenterology 2012 ; 6) : 1502 – 9 . 
52 . Tenner S . Initial management of acute pancreatitis: critical decisions 
during the fi rst 72 hours . Am J Gastroenterol 2004 ; 99 : 2489 – 94 . 
53 . Banks PA , Freeman ML . Practice guidelines in acute pancreatitis . Am J 
Gastroenterol 2006 ; 101 : 2379 – 400 . 
54 . Freeman MF , Werner J , van Santvoort HC et al. Interventions for 
necrotizing pancreatitis. Summary of a multi-disciplinary consensus conference 
.Pancreas 2012 ; 8 : 1176 – 94 . 
55 . Perez A , Whang EE , Brooks DC et al. Is severity of necrotizing 
pancreatitis increased in extending necrosis and infected necrosis? Pancreas 
2002 ; 25 : 229 – 33 . 
56 . Bakker OJ , van Santvoort H , Besselink MG et al. Extrapancreatic necrosis 
without pancreatic parenchymal necrosis: a separate entity in necrotising 
pancreatitis? Gut 2012 ; 18 : 143 – 9 
57 . Ranson JH , Pasternack BS . Statistical methods for quantifying the severity 
of clinical acute pancreatitis . J Surg Res 1977 ; 22 : 79 – 91 . 
58 . Knaus WA , Draper EA , Wagner DP et al. APACHE II: a severity of 
disease 
classifi cation system . Crit Care Med 1985 ; 13 : 818 – 29 . 
 85 
 
59 . Wu BU , Johannes RS , Sun X et al. Th e early prediction of mortality in 
acute pancreatitis: a large population-based study . Gut 2008 ; 57 : 1698Y1703 . 
60 . Papachristou GI , Muddana V , Yadav D et al. Comparison of BISAP, 
Ranson’s, APACHE-II, and CTSI scores in predicting organ failure, 
complications, and mortality in acute pancreatitis . Am J Gastroenterol 
2010 ; 105 : 435 – 41 . 
61 . Wu BU , Johannes RS , Sun X et al. Early changes in blood urea nitrogen 
predict mortality in acute pancreatitis . Gastroenterology 2009 ; 137 : 129 – 35 . 
62 . Mounzer R et al. Comparison of existing clinical scoring systems to predict 
persistent organ failure in patients with acute pancreatitis . Gastroenterology 
2012 ; 142 : 1476 – 82 . 
63 . Brown A , Orav J , Banks PA . Hemoconcentration is an early marker for 
organ failure and necrotizing pancreatitis . Pancreas 2000 ; 20 : 367 – 72 . 
64 . Lankisch PG , Mahlke R , Blum T et al. Hemoconcentration: an early 
marker of severe and/or necrotizing pancreatitis? A critical appraisal . 
Am J Gastroenterol 2001 ; 96 : 2081 – 5 . 
65 . Frossard JL , Hadengue A , Pastor CM . New serum markers for the 
detection of severe acute pancreatitis in humans . Am J Respir Crit Care Med 
2001 ;164 : 162 – 70 . 
66 . Papachristou GI , Whitcomb DC . Infl ammatory markers of disease 
severity 
in acute pancreatitis . Clin Lab Med 2005 ; 25 : 17 – 37 . 
 86 
 
67 . Balthazar EJ , Robinson DL , Megibow AJ e t al. Acute pancreatitis: value 
of CT in establishing prognosis . Radiology 1990 ; 174 : 331 – 6 . 
68 . van Santvoort HC , Besselink MG , Bakker OJ et al. A step-up approach 
or open necrosectomy for necrotizing pancreatitis . New Engl J Med 
2013 ; 362 : 1491 – 502 . 
69 . Tran DD , Cuesta MA . Evaluation of severity in patients with acute 
pancreatitis Am J Gastroenterol 1992 ; 87 : 604 – 8 . 
70 . Mofi di R , Duff MD , Wigmore SJ et al. Association between early 
systemic infl ammatory response, severity of multiorgan dysfunction and death 
in acute pancreatitis . Br J Surg 2006 ; 93 : 738 – 44 . 
71 . Buter A , Imrie CW , Carter CR et al. Dynamic nature of early organ 
dysfunction determines outcome in acute pancreatitis . Br J Surg 2002 ; 89 : 
298 – 302 . 
72 . Papachristou GI , Muddana V , Yadav D et al. Increased serum creatinine is 
associated with pancreatic necrosis in acute pancreatitis . Am J Gastroenterol 
2010 ; 105 : 1451 – 2 . 
73 . Heller SJ , Noordhoek E , Tenner SM et al. Pleural eff usion as a predictor 
of severity in acute pancreatitis . Pancreas 1997 ; 15 : 222 – 5 . 
74 . Funnell IC , Bornman PC , Weakley SP et al. Obesity: an important 
prognostic factor in acute pancreatitis . Br J Surg 1993 ; 80 : 484 – 6 . 
75 . Mann DV , Hershman MJ , Hittinger R et al. Multicentre audit of death 
from acute pancreatitis . Br J Surg 1994 ; 81 : 890 – 3 . 
 87 
 
76 . Mutinga M , Rosenbluth A , Tenner SM et al. Does mortality occur early or 
late in acute pancreatitis? Int J Pancreatol 2000 ; 28 : 91 – 5 . 
77 . Johnson CD , Abu-Hilal M . Persistent organ failure during the fi rst 
week as a marker of fatal outcome in acute pancreatitis . Gut 2004 ; 53 : 
1340 – 4 . 
78 . Lytras D , Manes K , Triantopoulou C et al. Persistent early organ failure: 
defi ning the high risk group of patients with severe acute pancreatitis . 
Pancreas 2008 ; 36 : 249 – 54 . 
79 . Kerner T , Vollmar B , Menger MD et al. Determinants of pancreatic 
microcirculation 
in acute pancreatitis in rats . J Surg Res 1996 ; 62 : 165 – 71 . 
80 . Bassi D , Kollias N , Fernandez-del Castillo C et al. Impairment of 
pancreatic 
microcirculation correlates with the severity of acute experimental 
pancreatitis . J Am Coll Surg 1994 ; 179 : 257 – 63 . 
81 . Inoue K , Hirota M , Beppu T et al. Angiographicfeatures in acute 
pancreatitis: the severity of abdominal vessel ischemic change refl ects the 
severity 
of acute pancreatitis . JOP 2003 ; 4 : 207 – 13 . 
82 . Bize P , Platon A , Becker C . Perfusion measurement in acute pancreatitis 
using dynamic perfusion MD CT . Am J Radiol 2006 ; 186 : 114 – 8 . 
 
 88 
 
83 . Wu BU , Hwang JQ , Gardner TH et al. Lactated Ringer’s solution reduces 
systemic infl ammation compared with saline in patients with acute 
pancreatitis . Clin Gastroenterol Hepatol 2011 ; 9 : 710 – 7 . 
84 . Takeda K , Mikami Y , Fukuyama S et al. Pancreatic ischemia associated 
with vasospasm in the early phase of human acute necrotizing pancreatitis 
. Pancreas 2005 ; 30 : 40 – 9 . 
85 . Gardner TB , Vege SS , Chari ST et al. Faster rate of initial fl uid 
resuscitation in severe acute pancreatitis diminishes in-hospital mortality . 
Pancreatology 
2009 ; 
86 . Warndorf MG , Kurtzman JT , Bartel MJ et al. Early fl uid resuscitation 
reduces morbidity among patients with acute pancreatitis . Clin Gastroenterol 
Hepatol 2011 ; 9 : 705 – 9 . 
87 . Mao EQ , Fei J , Peng YB et al. Rapid hemodilution is associated with 
increased sepsis and mortality among patients with severe acute 
pancreatitis . Chin Med J (Engl) 2010 ; 123 : 1639 – 44 . 
88 . de-Madaria E , Soler-Sala G , S á nchez-Paya J et al. Infl uence of fl uid 
therapy on the prognosis of acute pancreatitis: a prospective cohort study . 
Am J Gastroenterol 2011 ; 106 : 1843 – 50 . 
89 . Khajavi MR , Etezadi F , Moharari RS et al. Eff ects of normal saline vs. 
lactated Ringer’s during renal transplantation . Renal Fail 2008 ; 30 : 535 – 9 . 
 
 89 
 
90 . Cho YS , Lim H , Kim SH . Comparison of lactated Ringer’s solution and 
0.9% saline in the treatment of rhabdomyolysis induced by doxylamine 
intoxication . Emerg Med J 2007 ; 24 : 276 – 80 . 
91 . Eckerwall G , Olin H , Andersson B et al. Fluid resuscitation and nutritional 
support during severe acute pancreatitis in the past: what have we learned 
and how can we do better? Clin Nutr 2006 ; 25 : 497 – 504 . 
92 . Acosta JM , Ledesma CL . Gallstone migration as a cause of acute 
pancreatitis . N Engl J Med 1974 ; 290 : 484 – 7 . 
93 . Neoptolemos JP , London NJ , James D et al. Controlled trail of urgent 
endoscopic retrograde cholangiopancreatography and endoscopic 
sphincterotomy versus conservative management for acute pancreatitis due to 
gallstones . Lancet 1988 ; 3 : 979 – 83 . 
94 . Fan ST , Lai EC , Mok FP et al. Early treatment of acute biliary pancreatitis 
by endoscopic papillotomy . New Engl J Med 1993 ; 328 : 228 – 32 . 
95 . Folsch UR , Nitsche R , Ludtke R et al. Early ERCP and papillotomy 
compared with conservative treatment for acute biliary pancreatitis . 
N Engl J Med 1997 ; 336 : 237 – 42 . 
96 . Arguedas MR , Dupont AW , Wilcox CM . Where do ERCP, endoscopic 
ultrasound, magnetic resonance cholangiopancreatography, and intraoperative 
cholangiography fi t in the management of acute biliary pancreatitis? 
A decision analysis model . Am J Gastroenterol 2001 ; 96 : 2892 – 9 . 
 
 90 
 
97 . Moretti A , Papi C , Aratari A et al. Is early endoscopic retrograde 
cholangiopancreatography useful in the management of acute biliary 
pancreatitis? A meta-analysis of randomized controlled trials . Div Liver 
Dis 2008 ; 40 : 379 – 85 . 
98 . Freeman ML , DiSario JA , Nelson DB et al. Risk factors for post-ERCP 
pancreatitis: a prospective, multicenter study . Gastrointest Endosc 
2001 ; 54 : 425 – 34 . 
99 . Mehta SN , Pavone E , Barkun JS et al. Predictors of post-ERCP complica 
tions 
in patients with suspected choledocholithiasis . Endoscopy 1998 ; 30 : 457 – 63 
100 . Lella F , Bagnolo F , Colombo E et al. A simple way of avoiding post-
ERCP 
pancreatitis . Gastrointest Endosc 2004 ; 59 : 830 – 4 . 
 
 
 
 
 
 
 
 
 
 91 
 
 
 
 
 
 
 
 
 
